CELZ
Creative Medical Technology Holdings, Inc.2.0900
-0.0300-1.42%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
5.39MP/E (TTM)
-Basic EPS (TTM)
-2.84Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Creative Medical Technology Holdings posted a Q2 net loss of $1.2M, narrower than the $1.6M loss a year earlier, while YTD net loss widened to $2.9M from $2.6M despite flat $3K revenue. Operating expenses dropped 22% y/y to $1.3M in Q2, driven by 46% lower R&D spending on timed partner efforts, though YTD R&D edged down just 8% amid back pain trial advances. Cash climbed to $6.5M on $3.7M warrant exercise proceeds, yielding positive $0.6M operating cash flow after $2.8M burn; no debt burdens the balance sheet. Warrant exercises boosted shares to 2.58M, aligning with $0.48 diluted EPS versus 2.58M weighted shares—no anti-dilution noted. Dosed second cohort in AlloStemSpine back pain trial without safety issues. Yet rapid tech shifts threaten product relevance.
10-Q
Q1 FY2025 results
Creative Medical Technology Holdings notched its first revenue of $3,000 in Q1 FY2025 ended March 31, 2025, up from zero a year earlier, though the $1,800 gross profit couldn't offset a 76% surge in R&D to $743,304 driven by the CELZ-201 ADAPT back pain trial. Operating loss widened to $1.66M from $1.12M y/y, while net loss hit $1.64M versus $1.04M, with the gap to operating mainly from minimal stock-based comp. Cash climbed to $7.7M on $3.4M net from warrant exercises, funding ongoing trials without debt. Warrant inducement closed March 6 for $3.7M net, bolstering liquidity. Yet rapid tech shifts in biotech could sideline unproven therapies.
8-K
Stockholders approve warrant exercise
Creative Medical Technology Holdings stockholders approved the full exercise of 1,799,774 warrants issued on March 6, 2025, at a special meeting on May 5, 2025. With 35.0% of shares present, voting tallied 308,051 for, 39,229 against, and 466,282 abstentions. This influx of capital bolsters the company's resources. Yet high abstentions signal mixed investor sentiment.
8-K
Nasdaq clawback compliance resolved
Creative Medical Technology Holdings adopted a Clawback Policy on April 4, 2025, retroactive to December 1, 2023, to comply with Nasdaq Listing Rule 5608(b)(1), filing it via an amended 10-K. Nasdaq notified the company on April 8 that prior delays in adoption and disclosure violated rules for fiscal years 2023 and 2024. Yet compliance is now affirmed; the issue is closed. No executive incentive pay faces clawback.
IPO
Employees
Sector
Industry
BCLI
BrainStorm Cell Therapeutics In
0.58+0.03
BSEM
BioStem Technologies, Inc.
3.84-0.11
CCEL
Cryo-Cell International, Inc.
3.80+0.06
CELU
Celularity Inc.
1.35-0.05
CLCS
Cell Source, Inc.
0.45+0.08
CLLS
Cellectis S.A.
4.06-0.73
MESO
Mesoblast Limited
18.29+0.58
RMTG
Regenerative Medical Technology
0.04+0.00
STME
Stimcell Energetics, Inc.
0.37-0.04
VCEL
Vericel Corporation
35.50-0.99